Adage Capital Partners Gp, L.L.C. Sarepta Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$51 Billion
Q1 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 470,000 shares of SRPT stock, worth $74.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

470,000

Holding current value

$74.3 Million

% of portfolio

0.12%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $44 Million - $66.5 Million	470,000 New	470,000 $60.8 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $9.74 Million - $11.7 Million	-95,000 Reduced 14.5%	560,000 $67.9 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $27.1 Million - $40 Million	254,650 Added 63.61%	655,000 $75 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $32.3 Million - $42.8 Million	-274,650 Reduced 40.69%	400,350 $55.2 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $21.2 Million - $27.7 Million	-210,000 Reduced 23.73%	675,000 $87.5 Million

Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $28.8 Million - $45.3 Million	-380,000 Reduced 30.04%	885,000 $97.8 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $15.7 Million - $22.1 Million	250,000 Added 24.63%	1,265,000 $94.8 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $23 Million - $33 Million	365,000 Added 56.15%	1,015,000 $79.3 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $19.3 Million - $24.9 Million	250,000 Added 62.5%	650,000 $58.5 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $2.66 Million - $3.72 Million	40,247 Added 11.19%	400,000 $37 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $25 Million - $31.2 Million	359,753 New	359,753 $28 Million
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $21.7 Million - $50.7 Million	-300,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $69.1 Million - $98.3 Million	-550,000 Reduced 64.71%	300,000 $51.1 Million
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $31.8 Million - $43.1 Million	-250,000 Reduced 22.73%	850,000 $119 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $86 Million - $159 Million	-925,000 Reduced 45.68%	1,100,000 $176 Million
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $77.2 Million - $123 Million	937,670 Added 86.24%	2,025,000 $198 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $48.8 Million - $86.4 Million	-637,626 Reduced 36.96%	1,087,330 $140 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $38.2 Million - $82.4 Million	524,956 Added 43.75%	1,724,956 $130 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $50.5 Million - $68.4 Million	-450,000 Reduced 27.27%	1,200,000 $182 Million
Q1 2019 May 15, 2019	SELL	$106.67 - $151.68 $74.7 Million - $106 Million	-700,144 Reduced 29.79%	1,650,000 $197 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $102 Million - $156 Million	1,050,144 Added 80.78%	2,350,144 $256 Million
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $28.1 Million - $39.3 Million	243,389 Added 23.03%	1,300,000 $210 Million
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $68.6 Million - $147 Million	956,611 Added 956.61%	1,056,611 $140 Million
Q1 2018 May 15, 2018	BUY	$54.02 - $82.27 $5.4 Million - $8.23 Million	100,000 New	100,000 $7.41 Million

Others Institutions Holding SRPT

# of Institutions

470

Shares Held

79.3M

Call Options Held

4.23M

Put Options Held

1.21M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $13.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Sarepta Therapeutics, Inc. Transaction History